NasdaqCM - Nasdaq Real Time Price USD

Eyenovia, Inc. (EYEN)

1.6700

+0.5400

+(47.79%)

At close: 4:00:01 PM EDT

1.6400

-0.03

(-1.80%)

After hours: 5:10:16 PM EDT

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Eyenovia and Betaliq continue to negotiate a binding merger agreement consistent with the previously announced signed Letter of Intent Reports continued progress on the development of the user-filled Optejet, and remains on track to file for U.S. device regulatory approval in September 2025 Reduced ongoing cash burn by approximately 70% versus prior year and improved debt repayment terms LAGUNA HILLS, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technolog

GlobeNewswire 23 hours ago

EYEN
+47.79%
Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

On track for regulatory submission seeking marketing approval of the Optejet UFD in Q4 2025NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today provided an update on recent progress made in the development of the Company’s novel Optejet UFD. The user-filled Optejet is desi

GlobeNewswire last month

EYEN
+47.79%
Eyenovia Shares Drop 14% Amid Betaliq Merger Talks

The proposed deal values Betaliq at $77 million and Eyenovia at $15 million.

GuruFocus.com last month

EYEN
+47.79%
Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Combination, if successful, would create a new publicly-listed eye care company combining Betaliq’s EyeSol® water-free drug delivery technology for glaucoma with Eyenovia’s Optejet® device platform The combined company would continue marketing Eyenovia’s FDA-approved products – and plans to in-license additional products to generate near-term revenue NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developi

GlobeNewswire last month

EYEN
+47.79%
Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company"), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has been informed by staff of The Nasdaq Stock Market LLC that the Company has regained compliance with all Nasdaq Capital Market continued listing requirements, including Nasdaq Listing Rule 5550(a)(2), the minimum bid price requirement rule, and Listing Rule 5810(c)

GlobeNewswire 2 months ago

EYEN
+47.79%
Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

Amendment provides financial flexibility to the Company by deferring all interest as well as principal redemption payments through September 2025, while reducing near-term cash needsNEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announced that it has entered into an amendment to its outstanding senior secured convertible debt due N

GlobeNewswire 2 months ago

EYEN
+47.79%
Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Eyenovia plans to submit for U.S. device regulatory approval in Q4 of this year, marking a key step toward commercializationNEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet® device, today announces recent progress on the development of its user-filled spray dispenser. “Millions of consumers have difficulty with traditional eye drops, including diff

GlobeNewswire 3 months ago

EYEN
+47.79%
Top Midday Decliners

Blue Hat Interactive Entertainment Technology (BHAT) said late Tuesday that the Nasdaq Stock Market

PREMIUM
MT Newswires 3 months ago

BHAT

EYEN
+47.79%

MANH
Eyenovia Announces 1-for-80 Reverse Stock Split

Reverse stock split, when effective, is intended to restore compliance with the Nasdaq minimum bid price requirement while Eyenovia continues to evaluate a broad range of strategic alternativesNEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that its Board of Directors approved a 1-

GlobeNewswire 3 months ago

EYEN
+47.79%
Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Virtual meeting scheduled for 10:00 a.m. ET on January 21st; stockholders must pre-register by 11:59 p.m. ET on January 20thNEW YORK, Jan. 15, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company, today announced that the two leading independent proxy advisory firms, Institutional Shareholder Services Inc. (“ISS”) and Glass Lewis & Co. (“Glass Lewis”), have recommended that Eyenovia stockholders entitled to vote at the Company’s 2

GlobeNewswire 4 months ago

EYEN
+47.79%
Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Company concurrently focused on completing development of the Gen-2 user-filled Optejet® device by 3Q 2025 while reducing spend by over 60%NEW YORK, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company focused on completing development of its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has engaged Chardan as its financial advisor in connection with its evaluation of strat

GlobeNewswire 4 months ago

EYEN
+47.79%
Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

NEW YORK, Dec. 06, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 20,085,025 shares of its common stock (or common stock equivalents in lieu t

GlobeNewswire 5 months ago

EYEN
+47.79%
Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

NEW YORK, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, today announced that it has entered into a securities purchase agreement with a healthcare focused institutional investor for the purchase and sale of 12,081,785 shares of its common stock (or common stock equivalents in lieu t

GlobeNewswire 5 months ago

EYEN
+47.79%
Eyenovia taking additional actions to reduce personnel-related costs by over 70%

Eyenovia (EYEN) announced that Avenue Capital Management has agreed to support a potential restructuring of Eyenovia’s Loan and Security Agreement and has agreed to defer principal and interest payments on its outstanding debt until the end of February 2025. Eyenovia also announced that it is taking additional actions that are intended to reduce the Company’s ongoing personnel-related costs by over 70%. “We are grateful to Avenue Capital for the support they have demonstrated during this challen

TipRanks 5 months ago

EYEN
+47.79%
Eyenovia Provides Update on Restructuring Efforts

Avenue Capital agrees to Company’s deferral of principal and interest payments on its outstanding debt until the end of February 2025 Eyenovia continues to evaluate a broad range of strategic alternatives to maximize stakeholder value NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company, today provided an update on its ongoing restructuring efforts. The Company announced today that Avenue Capital Management L.P. has agreed to support a poten

GlobeNewswire 5 months ago

EYEN
+47.79%
Eyenovia downgraded to Neutral from Buy at H.C. Wainwright

H.C. Wainwright downgraded Eyenovia (EYEN) to Neutral from Buy with a price target of $2, down from $12. Based on the announced independent data review committee determining the Phase 3 CHAPERONE study did not meet its primary endpoint of less than 0.5 diopter progression in visual acuity over the three-year timeframe, the Optejet device continues to need a substantial indication for mainstream adoption, the analyst tells investors in a research note. The firm says that with the CHAPERONE study

TipRanks 5 months ago

EYEN
+47.79%
Eyenovia Stock Tumbles on Termination of Phase III Myopia Study

EYEN stock craters on the decision to terminate late-stage myopia study of MicroPine following negative feedback from an independent Data Review Committee.

Zacks 5 months ago

EYEN
+47.79%

PFE
Eyenovia stock plummets following Phase III myopia trial failure

The failure of Eyenovia's CHAPERONE study has seen the company’s stock value drop drastically as it considers options and contingencies.

Clinical Trials Arena 5 months ago

EYEN
+47.79%
Sector Update: Health Care Stocks Slide Late Afternoon

Sector Update: Health Care Stocks Slide Late Afternoon

PREMIUM
MT Newswires 6 months ago

EYEN
+47.79%
Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

On Friday, Eyenovia, Inc. (NASDAQ:EYEN) stock is trading lower after an update from the Phase 3 CHAPERONE study evaluating its proprietary drug-device combination of low-dose atropine in the company’s Optejet dispensing platform pediatric progressive myopia. Progressive myopia is a type of nearsightedness that worsens over time due to the eyeball growing too long. The company said that an independent Data Review Committee (DRC) reviewed the CHAPERONE data and found that the trial is not meeting

Benzinga 6 months ago

EYEN
+47.79%

Performance Overview

Return	EYEN	S&P 500 (^GSPC)
YTD	-85.70%	+1.00%
1-Year	-97.18%	+11.91%
3-Year	-98.97%	+52.27%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Eyenovia, Inc. (EYEN)

Eyenovia Provides Updates on Potential Merger with Betaliq and Development of the Optejet User Filled Device (UFD), and Reports First Quarter 2025 Financial Results

Eyenovia Provides Development Update on Optejet User Filled Device (UFD)

Eyenovia Shares Drop 14% Amid Betaliq Merger Talks

Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq

Eyenovia Regains Compliance with All Nasdaq Continued Listing Requirements

Eyenovia, Inc. Announces Debt Restructuring Including Amendment to Senior Secured Debt, Improving Cash Runway to Allow for the Evaluation of Strategic Alternatives

Eyenovia Announces Progress on Next-Generation User-Filled Optejet Dispensing Device

Top Midday Decliners

Eyenovia Announces 1-for-80 Reverse Stock Split

Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders

Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives

Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering

Eyenovia, Inc. Announces Pricing of $1.3 Million Registered Direct Offering

Eyenovia taking additional actions to reduce personnel-related costs by over 70%

Eyenovia Provides Update on Restructuring Efforts

Eyenovia downgraded to Neutral from Buy at H.C. Wainwright

Eyenovia Stock Tumbles on Termination of Phase III Myopia Study

Eyenovia stock plummets following Phase III myopia trial failure

Sector Update: Health Care Stocks Slide Late Afternoon

Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline

Performance Overview